By: Ni Nengah Dwi Fatmawati, Gede Ngurah Rsi Suwardana, Komang Ayu Nocianitri, I Ketut Mariadi, I Nengah Sujaya
ABSTRACT
Inflammatory bowel disease (IBD) is an inflammatory disorder of the digestive tract. Increased intestinal level of the proinflammatory cytokine TNF-α is associated with disease severity. IBD occurs as results of many factors, including dysbiosis. It is well-established that gut microbiota plays role in mucosa immunity, then modulation of gut microbiota may help in alleviating IBD symptoms. Probiotics could modulate gut microbiota. Weissella confusa F213 (WCF213) has been found to successfully enhance mucosa integrity in vitro. The role of this local probiotic in immunomodulation on intestinal mucosa has not been investigated yet. Therefore, the aim of this study was to evaluate the effect of WCF213 on TNF-a level in colon mucosa of DSS-induced colitis rats. Sixteen male Wistar rats (± 100 g) were divided into 4 groups; control, WCF213 (1 x 108 CFU/BW) for 14 d, 2.5% Dextran Sulphate Sodium (DSS) for 7 d and WCF213 (1 x 108 CFU/BW) for 14 day, and 2.5% DSS for 7 d. After sacrificing the rats, the colon was collected, and mucosal TNF-a level was measured using ELISA. It was found that TNF-a level of DSS-WCF213-treated group was significantly lower than that of DSS-treated group (p=0.011). In IBD, there is an elevation of TNF-α tissue level in the mucosa and lamina propria of colon. Therefore, this preliminary finding indicated that W. confusa F213 may play a role in IBD management. Further investigation on other inflammatory markers and mucosal integrity are needed to study the role of this probiotic in IBD.
Keywords: Weissella confusa, Inflammatory Bowel Disease, Colitis, Dextran Sulphate Sodium, TNF-a
*This poster was presented in The 6th International Conference of Indonesian Society for Lactic Acid Bacteria and Gut Microbiota (6th ISLAB) on 13th August 2021
More information about the poster -> Click here
More information about the event -> Click here